**Vincristine**

**Indication**: Kaposi sarcoma of unspecified primary site  
**ICD11 code**: 2C27.Z

**INN**: Vincristine

**Medicine type**: Chemical agent

**List type**: Complementary (EML)  
(EMLc)

**Formulations**: Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)

**EML status history**
- First added in 2015 (TRS 994)
- Changed in 2019 (TRS 1021)
- Changed in 2021 (TRS 1035)

**Sex**: All

**Age**: Also recommended for children

**Therapeutic alternatives**: The recommendation is for this specific medicine

**Patent information**: Patents have expired in most jurisdictions  
Read more about patents.

**Tags**: Cancer

**Wikipedia**: Vincristine

**DrugBank**: Vincristine

---

**Summary of evidence and Expert Committee recommendations**

The Expert Committee recommended the addition of new strength formulations of vincristine IV injection (1mg/mL and 2 mg/2mL) to the EML and EMLc.